[PSA doubling time as a new diagnostic and prognostic method for prostate cancer].
OBJECTIVE
To review the value of PSA kinetics in the diagnosis and prognosis of prostate cancer.


METHODS
Review of the literature through a Medline search.


CONCLUSIONS
A pre-tretament PSAV value >2ng/ ml/yr is a risk factor for increased mortality from prostate cancer after surgery or radiation therapy. A PSADT<3ms is indicative of reduced survival after treatment. For patients with PSA recurrence after surgery a PSADT> 10 is more likely associated with local recurrence.
Llorente
Carlos
C
Servicio de Urología, Fundacion Hospital Alcorcón, Profesor Asociado de Cirugía Universidad Rey Juan Carlos, Madrid, España. cllorente@fhalcorcon.es
de la Morena
José Manuel
JM
Ardura
Manuel Alvarez
MA
D006801:Humans; D008297:Male; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000628:therapy; D013997:Time Factors
D017430:Prostate-Specific Antigen